By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK (GSK) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...

U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg ...

Detailed price information for Upstream Bio Inc (UPB-Q) from The Globe and Mail including charting and trades.

Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

Please provide your email address to receive an email when new articles are posted on . Patients with both chronic rhinosinusitis with nasal polyps and asthma experience greater disease severity and ...

Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammation Kenneth Mendez, President and CEO of the Asthma and Allergy Foundation of America (AAFA), ...

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...